Similar articles

• Major progress toward eliminating lymphatic filariasis.

  Ottesen EA. Ottesen EA. N Engl J Med. 2002 Dec 5;347(23):1885-6. doi: 10.1056/NEJMe020136. N Engl J Med. 2002. PMID: 12466515 No abstract available.
• Unfulfilled potential: using diethylcarbamazine-fortified salt to eliminate lymphatic filariasis.

  Lammie P, Milner T, Houston R. Lammie P, et al. Bull World Health Organ. 2007 Jul;85(7):545-9. doi: 10.2471/blt.06.034108. Bull World Health Organ. 2007. PMID: 17768503 Free PMC article.
• Mass drug administration of ivermectin, diethylcarbamazine, plus albendazole compared with diethylcarbamazine plus albendazole for reduction of lymphatic filariasis endemicity in Papua New Guinea: a cluster-randomised trial.

  Laman M, Tavul L, Karl S, Kotty B, Kerry Z, Kumai S, Samuel A, Lorry L, Timinao L, Howard SC, Makita L, John L, Bieb S, Wangi J, Albert JM, Payne M, Weil GJ, Tisch DJ, Bjerum CM, Robinson LJ, King CL. Laman M, et al. Lancet Infect Dis. 2022 Aug;22(8):1200-1209. doi: 10.1016/S1473-3099(22)00026-3. Epub 2022 May 6. Lancet Infect Dis. 2022. PMID: 35533701 Free PMC article. Clinical Trial.
• Towards elimination of lymphatic filariasis in India.

  Das PK, Ramaiah KD, Augustin DJ, Kumar A. Das PK, et al. Trends Parasitol. 2001 Oct;17(10):457-60. doi: 10.1016/s1471-4922(01)02056-6. Trends Parasitol. 2001. PMID: 11587940 Review.
• Lymphatic filariasis: constraints ahead.

  Mishra CP, Singh N. Mishra CP, et al. Indian J Public Health. 2003 Jan-Mar;47(1):27-30. Indian J Public Health. 2003. PMID: 14723292 Review. No abstract available.